After a slow couple of years, there are signs that biotech M&A activity is coming back into vogue, and a series of small transactions announced in the last few days provides further evidence of that trend.
![](https://static.wixstatic.com/media/04ef19_502d6d7c9c204b3ca111b85fc64992fa~mv2.jpg/v1/fill/w_147,h_119,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/04ef19_502d6d7c9c204b3ca111b85fc64992fa~mv2.jpg)
After a slow couple of years, there are signs that biotech M&A activity is coming back into vogue, and a series of small transactions announced in the last few days provides further evidence of that trend.